Long term I agree. But I am concerned in the near term that these data will raise expectations unduly for ALNY's PCKS9 phase 1 data readout shortly after the start of 2012. The trial is a single ascending dose in patients not allowed to be taking any cholesterol lowering drugs...
Market Data 
Markets 
AI
